Janney Montgomery Scott
IMDX

Janney Montgomery Scott’s Insight Molecular Diagnostics IMDX Stock Holding History

Janney Montgomery Scott’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-603
Closed -$17K – 2058
2018
Q4 		$17K Sell
603
-5
-0.8% -$180 ﹤0.01% 1927
2018
Q3 		$30K Buy
608
+6
+1% +$310 ﹤0.01% 2038
2018
Q2 		$31K Sell
602
-50
-8% -$2.46K ﹤0.01% 1976
2018
Q1 		$27K Buy
+652
New +$43.1K ﹤0.01% 1927

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janney Montgomery Scott's IMDX Position: Q1 2019 in Review

Janney Montgomery Scott sold out of Insight Molecular Diagnostics (IMDX) in Q1 2019, closing a stake of 603 shares — an estimated $17K sold.

Janney Montgomery Scott first reported a position in IMDX in Q1 2018 and held it in 4 quarters. The position peaked at $31K in Q2 2018. 50 funds tracked by Wall St. Rank hold IMDX as of Q1 2019.

  • Janney Montgomery Scott reported no remaining Insight Molecular Diagnostics position as of Q1 2019 after selling out during the quarter.
  • Janney Montgomery Scott sold 603 Insight Molecular Diagnostics shares in Q1 2019, an estimated $17K.
  • Janney Montgomery Scott first reported a position in Insight Molecular Diagnostics in Q1 2018 and held it in 4 quarters.
  • Janney Montgomery Scott's Insight Molecular Diagnostics position peaked at $31K in Q2 2018.
  • 50 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2019.

Based on Janney Montgomery Scott's 13F filing for Q1 2019, filed 30 Apr 2019.